Dimerix (DXB) Q1 2027 TU earnings summary

Executive summary

• September quarter strengthened funding, advanced DMX-200 Phase 3 and added DMX-652, a Phase 2-ready acute kidney injury asset.

• The Everest Medicines agreement was the fifth regional DMX-200 licence; upfront receipts across five agreements exceed A$80 million, with potential milestones of ~A$1.9 billion plus royalties.

Financial highlights

• Cash and cash equivalents rose to A$34.843 million at 30 September 2026 from A$16.154 million at 30 June 2026.

• Operating activities generated A$9.048 million net cash in the quarter, including A$14.146 million customer receipts and A$5.172 million R&D payments.

• Investing activities used A$7.138 million; financing activities generated A$16.656 million, including A$16.685 million borrowing proceeds.

• Reported cash receipts included the A$14.1 million Everest upfront payment; the quarter also included an approximately US$5 million upfront fee to acquire DMX-652.

Outlook and guidance

• Funding is stated to cover completion of ACTION3 Phase 3 and continued advancement of the DMX-652 Phase 2 program.

• DMX-200 ACTION3 final proteinuria endpoint is targeted for H1 2028; potential 2028 milestones include Phase 3 readout and NDA dossier submission.

• DMX-652 plans include Phase 2 initiation in 2026, first patient dosing and interim analysis in 2027, and Phase 2 readout and Phase 3 preparation in 2028.

• DMX-652 cash requirements are expected to remain modest near term; ACTION3 expenditure is expected to decrease as participants complete the trial.